GlassScriptPhysician profile
Sarah A Huseman
NPI 1316985385
$3,504.02
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $245 · 2021: $2,305 · 2022: $296.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $2,080.73 | 2019-2021 | |
| Allergan, INC. | $446.86 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $229.35 | 2019-2022 | |
| Glaukos Corporation | $112.32 | 2020-2022 | |
| Shire North American Group INC | $86.41 | 2019 | |
| Abbvie INC. | $72.37 | 2022 | |
| Alcon Vision LLC | $71.34 | 2019-2022 | |
| Lombart Brothers, INC. | $55.00 | 2019 | |
| Rxsight INC | $34.30 | 2020-2022 | |
| Quidel Corporation | $21.28 | 2019 | |
| Sight Sciences, INC. | $20.95 | 2021 | |
| Ocular Therapeutix, INC. | $12.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Huseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.